MedTrace Logo

Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease

NCT02783430 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-12-16

No results posted yet for this study

Summary

KetaPal is a placebo-controlled randomized trial designed to demonstrate the antidepressant action of ketamine in palliative care situations. Half of participants will receive Ketamine and Milnacipran in combination, while the other half will receive a Placebo and Milnacipran in combination.

Conditions

Interventions

DRUG

Ketamine

One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion

DRUG

Milnacipran

One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)

DRUG

Placebo

One single perfusion during 40 minutes at the beginning of the inclusion

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Antoine LEMAIRE, MD · Hospital of Valenciennes

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-08
Primary Completion
2024-03-08
Completion
2024-03-08

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02783430 on ClinicalTrials.gov